NCT07210528View on ClinicalTrials.gov

Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions
Mild Cognitive Impairment (MCI)Alzheimer Dementia (AD)
Interventions
DRUG

Emtricitabine (FTC)

"Capsule, 200mg FTC. White Opaque Body / Light Blue Opaque Cap with GILEAD and Gilead logo on body. 200 mg on cap printed in black."

DRUG

Descovy® (TAF/FTC)

Emtricitabine (FTC) 200 mg / Tenofovir Alafenamide (TAF) 25 mg. Tablets, Rectangular-Shaped, Debossed, Film-coated blue.

DRUG

Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25 mg.

Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25mg. Tablets, Rectangular-Shaped, Debossed, Film-Coated Blue.

DRUG

Placebo Capsules to Match Emtricitabine Capsules, 200mg.

"White Opaque Body/Light Blue Opaque Cap with GILEAD and Gilead logo on body, 200 mg on cap printed in black."

Trial Locations (1)

Unknown

RECRUITING

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER